The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: ACP-196 (Acalabrutinib) in Combination With Pembrolizumab, for Treatment of Hematologic Malignancies
Official Title: A Phase 1b/2 Proof-of-Concept Study of the Combination of ACP-196 (Acalabrutinib) and Pembrolizumab in Subjects With Hematologic Malignancies
Study ID: NCT02362035
Brief Summary: This study is evaluating the safety, pharmacodynamics (PD), and efficacy of acalabrutinib and pembrolizumab in hematologic malignancies.
Detailed Description: This is a Phase 1b/2, open-label, nonrandomized study that will be conducted in 2 stages. In the first stage, Part 1 of the study will determine the safety and preliminary efficacy of acalabrutinib and pembrolizumab in a limited group of B-cell malignancies. In the second stage, Part 2 allows for possible expansion cohorts into a wider range of B-cell malignancies, and Part 3 will evaluate the combination in subjects with myelofibrosis (MF).
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Research Site, Tucson, Arizona, United States
Research Site, Los Angeles, California, United States
Research Site, Denver, Colorado, United States
Research Site, Washington, District of Columbia, United States
Research Site, Niles, Illinois, United States
Research Site, Boston, Massachusetts, United States
Research Site, Rochester, Minnesota, United States
Research Site, Omaha, Nebraska, United States
Research Site, Columbus, Ohio, United States
Research Site, Greenville, South Carolina, United States
Research Site, Nashville, Tennessee, United States
Research Site, Dallas, Texas, United States
Research Site, Houston, Texas, United States
Research Site, San Antonio, Texas, United States
Research Site, Tyler, Texas, United States
Research Site, Fairfax, Virginia, United States
Research Site, Roanoke, Virginia, United States
Research Site, Vancouver, Washington, United States
Research Site, Yakima, Washington, United States
Name: AstraZeneca Clinical Study Information Center
Affiliation: 1-877-240-9479 - information.center@astrazeneca.com
Role: STUDY_DIRECTOR